PHI 101
Alternative Names: PHI-101Latest Information Update: 03 Feb 2025
At a glance
- Originator Pharos I&BT Co
- Developer Pharos iBio; Seoul National University Hospital
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 2 inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Preclinical Triple negative breast cancer
Most Recent Events
- 07 Dec 2024 Efficacy and adverse events data from phase Ia/Ib trial in Acute myeloid leukemia were presented at 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 23 Oct 2024 Pharmacodynamics data from a preclinical trial in Ovarian cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)